Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 25;14(1):5.
doi: 10.3390/md14010005.

New Drugs from Marine Organisms in Alzheimer's Disease

Patrizia Russo  1 , Aliaksei Kisialiou  2 , Palma Lamonaca  3 , Rossana Moroni  4 , Giulia Prinzi  5 , Massimo Fini  6
Affiliations
Review

New Drugs from Marine Organisms in Alzheimer's Disease

Patrizia Russo et al. Mar Drugs. .

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans.

Keywords: Alzheimer’s disease; bryostatin; clinical/preclinical studies; marine drugs; mechanisms of activity; new drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures. Chemical structures were drawn using ACD/ChemSketch®.
Figure 1
Figure 1
Chemical structures. Chemical structures were drawn using ACD/ChemSketch®.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Alzheimer Report 2015. [(accessed on 3 September 2015)]. Available online: http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.
    1. Sachdev P.S., Blacker D., Blazer D.G., Ganguli M., Jeste D.V., Paulsen J.S., Petersen R.C. Classifying neurocognitive disorders: The DSM-5 approach. Nat. Rev. Neurol. 2014;10:634–642. doi: 10.1038/nrneurol.2014.181. - DOI - PubMed
    1. Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet. Med. 2015 doi: 10.1038/gim.2015.117. - DOI - PMC - PubMed
    1. Hauser P.S., Narayanaswami V., Ryan R.O. Apolipoprotein E: From lipid transport to neurobiology. Prog. Lipid Res. 2011;50:62–74. doi: 10.1016/j.plipres.2010.09.001. - DOI - PMC - PubMed
    1. Kumar A., Ekavali A.S. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015;67:195–203. doi: 10.1016/j.pharep.2014.09.004. - DOI - PubMed

MeSH terms

LinkOut - more resources